IMMY nur die Besten tickern jung

buran und MfG

at Two Upcoming Investor Conferences12:05 04.03.14


PR Newswire

SAN DIEGO, March 4, 2014

SAN DIEGO, March 4, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.

On Monday, March 10, 2014, Mr. Baum is scheduled to present at the 26th Annual ROTH Conference at 5:30 pm PT at the Ritz-Carlton Laguna Niguel, California and will be available for one-on-one meetings for conference attendees through the conference request process. The presentation will also be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.imprimispharma.com.  

Later that week on Wednesday, March 12, 2014, Mr. Baum is scheduled to participate at the Northland Capital Markets 2014 Growth Conference at the Omni Berkshire Place Hotel located at 21 East 52nd Street New York, NY,  and will be available for one one-on-one meetings for conference attendees.  Any other meeting requests outside of these two appearances can be directed to the Imprimis IR Team at ir@imprimispharma.com.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis' patent-pending technologies and formulations are available today and are being prescribed by physicians.  For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; Imprimis' ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.


Quelle: PR Newswire

:::::::::::::::::::7,87 $ +1,29% +0,10 $

In Euro: 5,6789 € | Nasdaq, 13.03.14::::::: buran und MfG und danke und weitermachen

Zeit  Kurs  Stück  
20:59:42 7,90 $  100  
20:59:10 7,90 $  100  
20:58:54 7,90 $  100  
20:58:50 7,89 $  100  
20:56:11 7,90 $   400  
20:53:19 7,90 $  1.300  
20:53:19 7,89 $  100  
20:53:19 7,889 $  800  
20:51:30 7,851 $  100  
20:51:30 7,85 $  200  
20:51:30 7,86 $  200  
20:48:47 7,861 $  100  
20:45:50 7,90 $  100  
20:45:35 7,89 $  100  
20:44:36 7,88 $  500  
20:44:36 7,89 $  100  
20:41:19 7,90 $  100  
20:37:26 7,86 $  100  
20:37:11 7,86 $  300  
20:36:54 7,85 $  500  
20:36:48 7,85 $  500  
20:36:37 7,85 $  1.000  
20:36:34 7,86 $  600  
20:35:28 7,85 $  1.300  
20:35:03 7,84 $  800  
20:35:03 7,841 $  200  
20:32:14 7,849 $  700  
20:32:13 7,85 $  1.300  
20:30:25 7,85 $  700  
20:30:15 7,85 $  300  
20:10:42 7,83 $  100  
20:06:49 7,83 $  100  
20:05:53 7,83 $  300  
19:53:44 7,80 $  100  
18:52:51 7,80 $  1.000  
18:51:10 7,79 $  100  
18:33:44 7,7999 $  500  
18:10:01 7,75 $  500  
18:09:55 7,75 $  500  
18:09:51 7,75 $  500  
17:52:11 7,75 $  600  
17:41:48 7,75 $  100  
17:41:47 7,75 $  900  
17:37:45 7,75 $  1.000  
17:37:41 7,75 $  1.300  
17:37:39 7,75 $  2.500  
17:37:39 7,76 $  200  
17:27:03 7,76 $  100  
16:56:40 7,73 $  200  
16:53:30 7,6891 $  1.000  
16:16:09 7,76 $   200  
16:16:08 7,7699 $  2.200  
16:16:08 7,77 $  100  
16:12:28 7,75 $  400  
16:06:37 7,75 $  100  
16:05:40 7,75 $  100  
15:14:32 7,75 $  1.000  
15:03:54 7,77 $  700  
15:03:54 7,681 $  100  
15:03:54 7,77 $  300  
15:03:54 7,76 $  200  
15:02:49 7,763 $  500  

GrB

::::::::::::::::::: 7,90 $ +0,38% +0,03 $

In Euro: 5,6787 € | Nasdaq, 14.03.14::::::: von Sante Nirgendwo

Zeit  Kurs  Stück  
15:35:41 7,9799 $  125
_________________
GRATULATION

Preis pro share 7,95 $ Schleife 200 spread 1,92% buran und MfG und trullala und trallala

Bucheinsicht http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40 GrB

Bucheinsicht
http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40

buran und MfG und Thx und weitermachen und SCHICK

:::::::::::::::::::::::: 7,97 $ +3,24% +0,25 $

In Euro: 5,7225 € | Nasdaq, 18.03.14:::::: und nich schummeln beim TICKER FUMMELN

Börsenbuch http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40 GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
19.03.14 6,9201 7,9799 6,9201  7,42 $ 24.155 158 T

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
20.03.14 7,5499 7,5499 7,20  7,21 $ 28.469 207 T

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.03.14 7,288 7,52 6,94  6,95 $ 34.714 248 T

GrB

13th Annual Needham Healthcare Conference
11:05 25.03.14

PR Newswire

SAN DIEGO, March 25, 2014

SAN DIEGO, March 25, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 3:40 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.

Mr. Baum will be available for one-on-one meetings for conference attendees through the conference request process. Any other meeting requests outside of this event can be directed to the Imprimis IR Team at ir@imprimispharma.com. The April 9th presentation will be webcast and can be accessed on the "Events" page of the Company's website at www.imprimispharma.com.  

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis' patent-pending technologies and formulations are available today and are being prescribed by physicians.  For more information, please visit  or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; Imprimis' ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.


Quelle: PR Newswire

novel, and customizable medicines to physicians and patients at accessible prices. One of our key strategies to execute our business model is the use of compounding pharmacies to formulate and distribute to physicians and patients our proprietary compounded drug formulations and technologies. Through the initiation of customer relationships with our family of offerings, we hope to serve our customers’ needs and in turn grow our business.

Our hope is that through the success of our business, we will reduce healthcare costs and provide Americans access to high quality, novel and previously unavailable medicines.

Thank you for your interest in Imprimis Pharmaceuticals.

Mark L. Baum
Chief Executive Officerimprimispharma.com/

healthcare economy and solve unmet patient needs through the development and commercialization of proprietary sterile and topical drug formulations.imprimispharma.com/

and customizable medicines to physicians and patients at accessible prices. Working with leading inventor physicians and pharmacists, we evaluate intellectual property related to innovative compounded drug formulations in several areas, conduct a market-related review of a formulation, and validate the clinical experience of a development candidate outside of the inventor’s medical or pharmacy practice.  For development opportunities that pass our proprietary review methodology, we engage in development and commercialization activities in order to advance the expansion and ultimate commercial success of our growing proprietary compounded drug formulations portfolio.  We now own formulations in ophthalmology, wound management and urology that we believe may offer unique advantages over commercially available formulations, and are actively pursuing additional development opportunities.imprimispharma.investorroom.com/

imprimispharma.investorroom.com/index.php?s=43 GrB

Imprimis Pharmaceuticals, Inc.
12626 High Bluff Drive, Suite 150
San Diego, CA 92130
Phone: 858-704-4040
Fax: 858-345-1745
@Kosmonova buran,ISS Orbit
imprimispharma.com/contact/

Additional information about Imprimis and the presentations will be available to conference attendees who visit the Imprimis booth (#1481).

Imprimis' proprietary patent-pending ophthalmic compounded formulations are now available with a physician's prescription in many states while the Company continues its Go Dropless™ campaign (GoDropless.com/). The campaign was created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.

ABOUT DROPLESS OPHTHALMIC SURGERY FORMULATIONS

Imprimis acquired the intellectual property for these patent-pending formulations in August of 2013. As the Company stated at that time, the current treatment regimen for the prevention of post-cataract surgery complications is a costly pre-operative and post-operative patient-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive caregiver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues. Imprimis' unique drug formulations utilize a fourth generation quinolone therapy combined with anti-inflammatory agent, providing new choices for physicians to address the primary ocular complications of ophthalmic surgery - risk of infection and post-operative inflammation.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices. Imprimis is pioneering a new commercial pathway using compounding pharmacies for the formulation and distribution of its proprietary drug therapies which include formulations in ophthalmology, wound management and urology.  For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT:  Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.


Quelle: PR Newswire

Datum Erster Hoch Tief Schluss     Stücke Volumen
  09.05.14     6,831     6,831§6,755 6,79 $ 6.720 44.769

buran und MfG and FULL MÄDDÄLL DSCHÄGGÄDD

http://www.ariva.de/news/...ations-at-2014-Kiawah-Eye-Meeting-5053483 GrB

http://www.ariva.de/news/...yed-Would-Prefer-Dropless-Therapy-5079762 GrB

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium
14:05 24.07.14

PR Newswire

SAN DIEGO, July 24, 2014

SAN DIEGO, July 24, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations,  announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract surgery formulations will be delivered at the upcoming American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Valley, Utah from July 24 – 27, 2014.  

The American-European Congress of Ophthalmic Surgery is a unique collaboration of physicians, ophthalmic industry executives, select venture capitalists and technology entrepreneurs. The Society meets three times each year - in the US and Europe - to evaluate new developments in technology, surgical technique, clinical studies and progressive patient care. Its mission is to advance vision care and improve patients' quality of life through Innovation, Education and Advocacy.

Imprimis continues its Go Dropless™ campaign (dropless.com/), which has been created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations the company has developed in conjunction with physicians and pharmacists. Details of the AECOS presentations include:

Friday, July 25, 2014 – 9:20 a.m. – 9:30 a.m. MDT "Branded vs. Generic Options: What's Happening with Drop Prices? How Does It Impact the Premium Practice/Procedure?," Dr. Carlos Buznego
Sunday, July 27, 2014 - 7:08 a.m. – 7:16 a.m. MDT "Use of Intraocular Meds During Cataract Surgery with the Goal of Reducing or Eliminating Post-Op Drops," Dr. William Trattler
Imprimis' proprietary patent-pending ophthalmic compounded formulations are now available with a physician's prescription in 32 states and territories while the Company continues its Go Dropless™ campaign (GoDropless.com/). Currently two compounded antibiotic and steroid formulations are available in single, injectable, intraocular doses administered during cataract surgery. The preservative-free formulations generally contain 15 mg triamcinolone plus 1 mg moxifloxacin per ml and can also include vancomycin and the relative strengths of the active ingredients can be tailored to individual patients.  Advantages include reduction of compliance concerns, reduction of staff and chair time spent on instructions and follow-up with post-operative surgical patients, as well as calls from pharmacists. Two recent studies both found the use of these formulations to be positive in overall patient compliance, cost, and general experience.1-2

Furthermore, the company recently shared results of a survey of leading national cataract surgeons that showed 20 out of the 21 physicians surveyed expressed favorable opinions to the concept of Imprimis' single intraocular injection administered at the conclusion of cataract surgery.  These surgeons' perspectives examine the benefits of dropless cataract surgery for both doctors and patients. Specifically, the surgeons highlighted attributes related to convenience and compliance. To watch the complete video interviews, interested parties can go to www.GoDropless.com/why-go-dropless.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices. Imprimis is pioneering a new commercial pathway using compounding pharmacies for the formulation and distribution of its proprietary drug therapies which include formulations in ophthalmology, wound management and urology. For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; including its ability to maintain compliance with applicable state and federal laws and regulations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

1 Liegner J. Better surgery through chemicals. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.

2 Galloway MS. Intravitreal placement of antibiotic/steroid as a substitute for post-operative drops following cataract surgery. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.

MEDIA CONTACT:  Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals


Quelle: PR Newswire

http://www.ariva.de/news/...s-and-Provides-Operational-Update-5133819 GrB

:::::::::::::: 8,86 $ +7,39% +0,61 $
In Euro: 6,9923 € | Nasdaq, 24.10.14::: ich hab Dir damals eine Ticker Laterne geschenkt

buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof

buran: auch ich war im Erziehungsheim lange eine Ewigkeit 228.10.14 20:01 #1
Mario Meierhof
29. September um 21:38 ·
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
http://www.ariva.de/forum/...rziehungsheim-lange-eine-Ewigkeit-510117

Ein Call ist in-the-money, wenn der Kassakurs des Basiswertes über dem Basispreis liegt. Ein Put ist in-the-money, wenn der Kassakurs des Basiswertes unter dem Basispreis liegt. http://www.ariva.de/extras/lexikon.m?begriff=In_the_money_Option

Börsenbuch
http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40 GrB

Börsenbuch dazu
http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40 GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  09.02.15      7,11     7,124§7,00 7,0095 $ 2.700 19.036

GrB

Zeit     Kurs Stück
  17:43:53§7,26 $ 100
  16:57:11§7,2402 $ 1.000
______________________
GRATULATION

..yöah

Buch
http://www.ariva.de/...icals,_inc.-aktie/times_and_sales?boerse_id=40 GrB

:::::::::::::::::::: 8,24 $ +0,98% +0,08 $
In Euro: 7,4137 € | Nasdaq, 02.07.15 ,GrB

http://www.ariva.de/news/...ry-Revenue-for-Third-Quarter-2015-5526095 GrB

http://www.ariva.de/news/...nded-Sinus-Medications-in-the-U-S-5526161 GrB

http://www.ariva.de/news/...nts-as-an-Alternative-to-Daraprim-5529384 GrB

ISIN: US45323A2015 Symbol: IMMYTyp: Aktie Aufnehmen in Watchlist/Depot
Imprimis Pharmaceuticals Announces New Economic Study Demonstrating $8.7 Billion in Potential Cost Savings over the Next 10 Years with the Adoption of Dropless Therapy™ http://www.ariva.de/news/...-the-Adoption-of-Dropless-Therapy-5532653

-- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, announced that it has commenced construction on the company's Allen, Texas compounding pharmacy and plans to register the pharmacy with the U.S. Food and Drug Administration (FDA) as a 503B sterile outsourcing facility under the Drug Quality and Security Act (DQSA) of 2013.  The DQSA was signed into law by President Obama on November 27, 2013 and created a new pathway, in which a compounding pharmacy can register with the FDA as an outsourcing facility. http://www.ariva.de/news/...he-FDA-as-an-Outsourcing-Facility-5537456

http://www.ariva.de/news/...-Full-Year-2015-Financial-Results-5670033 GrB

-- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the 28th Annual ROTH conference on Wednesday, March 16, 2016 at 12:30 p.m. (PDT) at Dana Point, Calif.  The presentation will be broadcast in a live webcast and an archive of the webcast will be available for 90 days following the event.  Access will be available at wsw.com/webcast/roth30/immy or on the Investor Relations section of Imprimis' website at www.ImprimisPharma.com.  An updated investor presentation is now available and can be viewed at http://imprimispharma.investorroom.com/corporate-presentations.  Imprimis will also be hosting one-on-one meetings and attendees can contact their ROTH representative to arrange a meeting. http://www.ariva.de/news/...-ROTH-Conference-on-March-16-2016-5671589

http://www.ariva.de/news/...ults-and-Provides-Business-Update-5693465 GrB

Quarter 2016 Financial Report Conference Call and Webcast on August 15, 2016 at 4:30 p.m. EDT
Montag, 01.08.2016 15:05 von PR Newswire  http://www.ariva.de/news/...s-to-host-its-second-quarter-2016-5832472

SAN DIEGO, August 1, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model, today reported it will release second quarter 2016 financial results after the close of trading on Monday, August 15,  2016.  The company will host a conference call at 4:30 p.m. EDT/1:30 p.m. PDT on the same day to discuss the financial results and recent business developments. http://www.ariva.de/news/...s-to-host-its-second-quarter-2016-5832472

please dial (877)-407-8035 for domestic callers or (201)-689-8035 for international callers.  To listen to the webcast, please visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A replay of the call will be available until September 15, 2016.  To access the replay, dial (877)-660-6853 domestically or (201)-612-7415 internationally and reference Conference ID: 13641964.     http://www.ariva.de/news/...s-to-host-its-second-quarter-2016-5832472

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding™ business model.  The company is focused on patient outcomes and affordability and offers high quality lower-cost custom compounded drugs in all 50 states.  Headquartered in San Diego, California, Imprimis owns and operates four dispensing facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com.  http://www.ariva.de/news/...s-to-host-its-second-quarter-2016-5832472

buran und MfG

Registered Direct Offering
Mittwoch, 22.03.2017 13:05 von PR Newswire  http://www.ariva.de/news/...o-raise-3-1-million-in-registered-6080431

Eton Pharmaceuticals Names Sean Brynjelsen Chief Executive Officer and Director
Freitag, 23.06.2017 14:00 von PR Newswire http://www.ariva.de/news/...s-sean-brynjelsen-chief-executive-6294371

Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST
SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release third quarter 2017 financial r... irdirect.net/IMMY/...e=pr_immy&pagination=1&per_page=5

www.imprimisrx.com/about-us/company-overview/

Hier übrigens die News zum Anstieg.

seekingalpha.com/news/...hortage-list-shares-ahead-51-percent

www.nasdaq.com/de/symbol/immy/real-time

m.benzinga.com/article/...%2Fimprimis-pharmaceuticals-inc.htm

wo ist das realistische KZ, wer hat den Wert im Depot?